Home / News / World /  Russian covid-19 vaccine Sputnik V elicit antibody response, led to no serious adverse events: Lancet

New Delhi: Russia’s recently approved covid-19 vaccine, Sputnik V, appears to be safe without any serious adverse effects, and has developed long-term antibody response in humans during clinical trials, according to preliminary results published in The Lancet journal on Friday.

Results from the two early-phase Russian non-randomised vaccine trials showed that the formulations of the two-part vaccine, Sputnik V, have a good safety profile with no serious adverse events detected over 42 days among the 76 subjects, and induces antibody responses in all participants within 21 days.

Secondary outcomes from the trial also suggest that the vaccines also produced a T cell response within 28 days that provides long-term immunity in the body.

India crosses 4 million cases
View Full Image
India crosses 4 million cases

Meanwhile, back home, the Centre identified 15 districts that have had a surge in cases over the past four weeks and advised the authorities concerned to carry out stringent containment measures, to ensure that social distancing norms are followed, and also to implement strict perimeter control, as well as initiate house-to-house search for covid cases.

Union health secretary Rajesh Bhushan held a review meeting on Friday with the local authorities, including state health secretaries, district collectors, and municipal commissioners, of Mysuru, Bengaluru Urban, Prakasam, Chittoor, Dakshina Kannada, Davangere, Ludhiana, Patiala, Ballari, Koppal, Coimbatore, Chennai, Kanpur Nagar, Salem, and Lucknow, in Maharashtra, Andhra Pradesh, Karnataka, Uttar Pradesh, and Tamil Nadu to take stock of the situation.

“They have been exhibiting higher active caseload, fatality rates and surge in covid-19 cases for the past four weeks," said the health ministry.

Early identification of cases is the key to containing the surge and the districts must ramp up testing capacity in hotspots and densely populated areas, the Centre said. Effective monitoring of people in home isolation and easy access to hospitals should be taken up on priority for people with disease progression, the government added.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Recommended For You
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsFeedbackRedeem a Gift CardLogout